TVCMALL
12.3.2023 08:16:39 CET | Business Wire | Pressemeddelelse
Nylig blev Mobile World Congress (MWC) 2023 afholdt i Barcelona, og det var en stor succes. Mere end 88 000 deltagere og 2400+ udstillere deltog i denne begivenhed, herunder mange leverandører af mobiltelefontilbehør og grossister. Som Europas førende one-stop-shop for mobiltilbehør og engros/integreret forsyningskædeserviceplatform, TVCMALL deltaget også i dette digitale/mobile arrangement. TVCMALL, der er baseret i Shenzhen, Kina, som er verdens elektroniske center, tilbyder kunder en B2B mobiltilbehør engros-, sourcing- og tilpasningsløsning. Forskellige klassiske mobiltelefoncovers med læderfinish, opladere med multifunktioner og Amorus bærbare karaokehøjtalere fra TVCMALL fik stor ros af de fremmødte.
Der er multimedier i denne pressemeddelelse. Se hele meddelelsen her: https://www.businesswire.com/news/home/20230307005694/da/
TVCMALL brings one-stop wholesale solution to MWC 2023 (Photo: Business Wire)
MWC er en af verdens vigtigste telekommunikations- og teknologimesser. I løbet af de sidste 4 dage er aspekter som den seneste trend inden for mobilteknologi inklusive intelligent udstyr, 5G-netværk, AI og digitalisering blevet introduceret og delt med resten af verden.
Under showet mødte TVCMALL mange gamle kunder og mange nye venner. Mange af dem er som følger:
- Top forhandlere og distributører af mobiltelefontilbehør online
- B2C platform sælgere, Dropshippere
- Fysiske butikker, supermarkedssælgere, teleselskaber
- Gave-Tilpasningskunder (især for myndigheder, virksomheder, skoler og andre offentlige ydelser)
- OEM & ODM & OBM kunder
- Detail & Mobiltelefon værksteder
Mange kunder har samarbejdet med TVCMALL i over ti år siden etableringen i 2008, og de er vokset og udviklet sig hurtigt med TVCMALL. De udtrykte deres store påskønnelse og store taknemmelighed til TVCMALL for at levere en one-stop shop til engros, sourcing, tilpassede tjenester og andre forsyningskædetjenester.
Hvorfor de vælger TVCMALL som énuundgåelig og vigtig langsigtet partner? Fordi TVCMALL tilbyder et komplet produktkatalog med mere end 600.000 SKU'er online, og hver uge opdateres 6.000 nye produkter. Engros-processen, marketingsupport og kundeservice er effektive. TVCMALL har gode intentioner om at vokse sammen med sine kunder.
TVCMALLs omfattende anskaffelsesomkostninger er relativt lave, servicekonsistens og stabilitet er meget stærk. Derfor foretrækker mange kunder one-stop-tjenesteudbydere som TVCMALL.
Under MWC har TVCMALL etableretgod kontakt med nogle fremragende produktleverandører og e-handelstjenesteudbydere (af mobile, 3C elektroniske enheder og tilbehør).
Ii den nærmeste fremtid, med kontinuerlig TVCMALL brand og platform opgradering, vil TVCMALL styrke sit mål, "At hjælpe iværksættere med at realisere deres drømme om at lancere og opretholde en succesfuld detailforretning", og vil overholde sin forretningsdriftsfilosofi "Together we thrive". Med hensyn til specifikke strategier vil TVCMALL følge de 4 følgende anvisninger:
- Platform branding —Betjen TVCMALL-platformen som et fremtidigt århundrede gammelt brand
- Produktisering af tjenesterne - alle tjenester fra TVCMALL sammen med ideen om produktisering.
- ProduktDyb pløjning — For at være den bedste skal du trives.
- Lokalisering af TVCMALL-tjenesten — Gå globalt og lokalisere: Start lokalt marketing- og serviceteam, dybdegående forståelse og effektiv service.
TVCMALL vil se dig igen i Barcelona 2024!
For at se dette indhold fra cts.businesswire.com, så skal du give din accept på toppen af denne side.
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20230307005694/da/
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum